Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy Analysis of the EMPHASIS- HF Study:Analysis of the EMPHASIS- HF Study

Background In EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure), eplerenone significantly reduced major cardiovascular events versus placebo in 2737 patients with mild symptoms of heart failure and an ejection fraction ofMethods and Results We further analyzed EMPHASIS-HF according to the use and dose of these background drug classes. Patients receiving 50% of target dose were considered to be receiving high doses; patients onConclusions Eplerenone provides substantial benefit on major events (with an acceptable safety profile) in patients with mild symptoms of systolic heart failure, even in those already receiving high doses of standard background therapies.Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00232180.